Barclays PLC Chroma Dex Corp. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Chroma Dex Corp. stock. As of the latest transaction made, Barclays PLC holds 70,072 shares of CDXC stock, worth $369,279. This represents 0.0% of its overall portfolio holdings.

Number of Shares

70,072

Previous 70,072 -0.0%

Holding current value

$369,279

Previous $256,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$2.51 - $3.8 $134,214 - $203,193	53,472 Added 322.12%	70,072 $256,000
Q2 2024 Aug 14, 2024	BUY	$2.44 - $4.32 $40,504 - $71,712	16,600 New	16,600 $46,000
Q4 2023 Feb 15, 2024	BUY	$1.28 - $1.6 $4,800 - $6,000	3,750 New	3,750 $5,000
Q4 2022 Feb 13, 2023	SELL	$1.25 - $1.94 $242,211 - $375,911	-193,769 Reduced 65.96%	100,000 $168,000
Q2 2022 Aug 12, 2022	BUY	$1.59 - $2.7 $136,992 - $232,629	86,159 Added 41.5%	293,769 $491,000
Q1 2022 May 16, 2022	SELL	$2.02 - $3.92 $1.15 Million - $2.23 Million	-568,691 Reduced 73.26%	207,610 $511,000
Q4 2021 Feb 14, 2022	SELL	$3.74 - $6.7 $674,845 - $1.21 Million	-180,440 Reduced 18.86%	776,301 $2.9 Million
Q3 2021 Nov 09, 2021	BUY	$6.05 - $10.41 $891,993 - $1.53 Million	147,437 Added 18.22%	956,741 $6 Million
Q2 2021 Aug 13, 2021	BUY	$6.66 - $10.92 $5.16 Million - $8.46 Million	774,833 Added 2247.78%	809,304 $7.98 Million
Q1 2021 May 13, 2021	BUY	$4.59 - $18.74 $79,131 - $323,077	17,240 Added 100.05%	34,471 $322,000
Q4 2020 Feb 11, 2021	SELL	$3.93 - $5.5 $21,151 - $29,601	-5,382 Reduced 23.8%	17,231 $83,000
Q3 2020 Nov 12, 2020	SELL	$4.01 - $5.56 $14,905 - $20,666	-3,717 Reduced 14.12%	22,613 $92,000
Q2 2020 Aug 12, 2020	BUY	$3.0 - $5.52 $38,067 - $70,043	12,689 Added 93.02%	26,330 $121,000
Q1 2020 May 13, 2020	SELL	$2.54 - $4.75 $69,519 - $130,007	-27,370 Reduced 66.74%	13,641 $44,000
Q4 2019 Feb 10, 2020	BUY	$2.83 - $4.61 $60,898 - $99,202	21,519 Added 110.4%	41,011 $177,000
Q3 2019 Nov 14, 2019	SELL	$3.83 - $4.72 $19,751 - $24,341	-5,157 Reduced 20.92%	19,492 $77,000
Q2 2019 Aug 14, 2019	BUY	$3.71 - $4.83 $49,662 - $64,654	13,386 Added 118.85%	24,649 $115,000
Q1 2019 May 15, 2019	BUY	$3.2 - $4.19 $34,694 - $45,427	10,842 Added 2575.3%	11,263 $48,000
Q4 2018 Feb 14, 2019	SELL	$2.8 - $4.22 $40,768 - $61,443	-14,560 Reduced 97.19%	421 $1,000
Q3 2018 Nov 14, 2018	BUY	$3.5 - $4.91 $899 - $1,261	257 Added 1.75%	14,981 $64,000
Q2 2018 Aug 14, 2018	SELL	$3.22 - $4.43 $159,051 - $218,819	-49,395 Reduced 77.04%	14,724 $54,000
Q1 2018 May 15, 2018	SELL	$4.05 - $6.46 $157,119 - $250,615	-38,795 Reduced 37.7%	64,119 $269,000
Q4 2017 Feb 14, 2018	BUY	$3.88 - $6.96 $316,701 - $568,103	81,624 Added 383.39%	102,914 $605,000
Q3 2017 Nov 14, 2017	BUY	$2.91 - $4.71 $61,953 - $100,275	21,290	21,290 $91,000

Others Institutions Holding CDXC

# of Institutions

Shares Held

17.2M

Call Options Held

66.7K

Put Options Held

8.2K

View Full List

About ChromaDex Corp.

Ticker CDXC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,350,896
Market Cap $360M
Description
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...

More about CDXC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account